Peter S Linsley

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. pmc Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression
    Peter S Linsley
    Rosetta Inpharmatics, LLC, 401 Terry Ave N, Seattle, WA 98109, USA
    Mol Cell Biol 27:2240-52. 2007
  2. ncbi request reprint Mustering the micromanagers
    Lee P Lim
    Nat Biotechnol 25:996-7. 2007
  3. ncbi request reprint Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215
    Sara A Georges
    Rosetta Inpharmatics LLC, Seattle, Washington WA 98109, USA
    Cancer Res 68:10105-12. 2008
  4. doi request reprint Identification of SULF2 as a novel transcriptional target of p53 by use of integrated genomic analyses
    B Nelson Chau
    Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck and Co, Inc, Seattle, Washington 98109, USA
    Cancer Res 69:1368-74. 2009
  5. doi request reprint Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γ
    Paul Warrener
    Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck and Co, Inc, Seattle, WA 98109, USA
    Apoptosis 17:691-701. 2012
  6. ncbi request reprint MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT
    Zhan Zhang
    Rosetta Inpharmatics LLC, Seattle, WA, USA
    Cell Cycle 8:2756-68. 2009
  7. pmc MicroRNA-like off-target transcript regulation by siRNAs is species specific
    Julja Burchard
    Rosetta Inpharmatics LLC, Seattle, Washington 98109, USA
    RNA 15:308-15. 2009
  8. pmc Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing
    Aimee L Jackson
    Rosetta Inpharmatics, LLC, Seattle, WA 98109, USA
    RNA 12:1197-205. 2006
  9. pmc PPARalpha siRNA-treated expression profiles uncover the causal sufficiency network for compound-induced liver hypertrophy
    Xudong Dai
    Informatics, Rosetta Inpharmatics, Seattle, Washington, United States of America
    PLoS Comput Biol 3:e30. 2007
  10. pmc MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression
    Irena Ivanovska
    Rosetta Inpharmatics LLC, 401 Terry Ave N, Seattle, WA 98109, USA
    Mol Cell Biol 28:2167-74. 2008

Detail Information

Publications39

  1. pmc Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression
    Peter S Linsley
    Rosetta Inpharmatics, LLC, 401 Terry Ave N, Seattle, WA 98109, USA
    Mol Cell Biol 27:2240-52. 2007
    ..Simultaneous silencing of these genes was more effective at blocking cell cycle progression than disruption of the individual genes. Thus, miR-16 coordinately regulates targets that may act in concert to control cell cycle progression...
  2. ncbi request reprint Mustering the micromanagers
    Lee P Lim
    Nat Biotechnol 25:996-7. 2007
  3. ncbi request reprint Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215
    Sara A Georges
    Rosetta Inpharmatics LLC, Seattle, Washington WA 98109, USA
    Cancer Res 68:10105-12. 2008
    ..Our results showing a role for miR-192/215 in cell proliferation combined with recent observations that these miRNAs are underexpressed in primary cancers support the idea that miR-192 and miR-215 function as tumor suppressors...
  4. doi request reprint Identification of SULF2 as a novel transcriptional target of p53 by use of integrated genomic analyses
    B Nelson Chau
    Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck and Co, Inc, Seattle, Washington 98109, USA
    Cancer Res 69:1368-74. 2009
    ..Thus, our integrated genomic approach has led to the identification of a novel mediator of p53 network biology...
  5. doi request reprint Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γ
    Paul Warrener
    Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck and Co, Inc, Seattle, WA 98109, USA
    Apoptosis 17:691-701. 2012
    ..These findings establish a link between synthetic lethality of PARPi in BRCA-network disrupted cells and interferon pathway activation triggered by genetic instability...
  6. ncbi request reprint MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT
    Zhan Zhang
    Rosetta Inpharmatics LLC, Seattle, WA, USA
    Cell Cycle 8:2756-68. 2009
    ..Thus, miR-210 influences the hypoxia response in tumor cells through targeting a key transcriptional repressor of the MYC-MAX network...
  7. pmc MicroRNA-like off-target transcript regulation by siRNAs is species specific
    Julja Burchard
    Rosetta Inpharmatics LLC, Seattle, Washington 98109, USA
    RNA 15:308-15. 2009
    ..Therefore, siRNA therapeutics may trigger microRNA-like silencing of many unintended targets in vivo, and the potential toxicities caused by these off-target gene regulations cannot be accurately assessed in rodent models...
  8. pmc Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing
    Aimee L Jackson
    Rosetta Inpharmatics, LLC, Seattle, WA 98109, USA
    RNA 12:1197-205. 2006
    ....
  9. pmc PPARalpha siRNA-treated expression profiles uncover the causal sufficiency network for compound-induced liver hypertrophy
    Xudong Dai
    Informatics, Rosetta Inpharmatics, Seattle, Washington, United States of America
    PLoS Comput Biol 3:e30. 2007
    ..When combined with phenotypic evaluation, our approach should help to unleash the full potential of siRNAs in systematically unveiling the molecular mechanism of biological events...
  10. pmc MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression
    Irena Ivanovska
    Rosetta Inpharmatics LLC, 401 Terry Ave N, Seattle, WA 98109, USA
    Mol Cell Biol 28:2167-74. 2008
    ..We also show that miR-106b overrides a doxorubicin-induced DNA damage checkpoint. Thus, miR-106b family members contribute to tumor cell proliferation in part by regulating cell cycle progression and by modulating checkpoint functions...
  11. ncbi request reprint T lymphocyte activation gene identification by coregulated expression on DNA microarrays
    Mao Mao
    Rosetta Inpharmatics LLC, Merck Research Laboratories, 401 Terry Avenue N, Seattle, WA 98109, USA
    Genomics 83:989-99. 2004
    ..Four of these ESTs were extended to novel full-length clones encoding T-cell-regulated proteins with predicted functions in GTP metabolism, cell organization, and signal transduction...
  12. pmc Functional genomics identifies therapeutic targets for MYC-driven cancer
    Masafumi Toyoshima
    Department of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 109:9545-50. 2012
    ..In summary, through a functional genomics approach, pathways essential in the context of oncogenic MYC but not to normal cells were identified, thus revealing a rich therapeutic space linked to a previously "undruggable" oncogene...
  13. ncbi request reprint Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
    Lee P Lim
    Rosetta Inpharmatics, Merck and Co, 401 Terry Avenue N, Seattle, Washington 98109, USA
    Nature 433:769-73. 2005
    ..Moreover, miR-1 and miR-124, and presumably other tissue-specific miRNAs, seem to downregulate a far greater number of targets than previously appreciated, thereby helping to define tissue-specific gene expression in humans...
  14. doi request reprint An optimized lentivirus-mediated RNAi screen reveals kinase modulators of kinesin-5 inhibitor sensitivity
    Richard A Klinghoffer
    Rosetta Inpharmatics LLC, Merck and Co, Inc, Seattle, WA 98109, USA
    Assay Drug Dev Technol 6:105-19. 2008
    ..These results demonstrate the feasibility of screening with large collections of lentiviral vectors to identify drug enhancers and suppressors...
  15. pmc Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions
    Steven R Bartz
    Rosetta Inpharmatics, LLC, Seattle, WA 98109, USA
    Mol Cell Biol 26:9377-86. 2006
    ..Thus, tumor cells having disruptions in BRCA1/2 network genes and TP53 together are more sensitive to cisplatin than cells with either disruption alone...
  16. pmc Myc-regulated microRNAs attenuate embryonic stem cell differentiation
    Chin Hsing Lin
    Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 4417, USA
    EMBO J 28:3157-70. 2009
    ..In contrast, knockdown of the endogenous miRNAs accelerate differentiation. Our data show that in ES cells c-Myc acts, in part, through a subset of miRNAs to attenuate differentiation...
  17. pmc Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity
    Aimee L Jackson
    Rosetta Inpharmatics, LLC, Seattle, WA 98109, USA
    RNA 12:1179-87. 2006
    ..Thus, short stretches of sequence complementarity to the siRNA or shRNA seed region are key to the silencing of unintended transcripts...
  18. ncbi request reprint Individual-specific variation of gene expression in peripheral blood leukocytes
    Jerald P Radich
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D4 100, Seattle, WA 98109, USA
    Genomics 83:980-8. 2004
    ..These studies demonstrate the feasibility of using DNA microarrays to measure the variations in gene expression of PBL from different individuals in response to environmental and genetic factors...
  19. pmc Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown mice
    Angus T De Souza
    Rosetta Inpharmatics, Merck and Co Inc, 401 Terry Avenue North, Seattle, WA 98109, USA
    Nucleic Acids Res 34:4486-94. 2006
    ..Together, these data validate the utility of the RNAi approach and suggest that siRNA can be used as a complement to classical knockout technology in gene function studies...
  20. ncbi request reprint MicroRNAs and cell cycle regulation
    Michael Carleton
    Rosetta Inpharmatics LLC, Seattle, Washington 98109, USA
    Cell Cycle 6:2127-32. 2007
    ..We discuss emerging evidence that support the idea that some microRNA activity may be cell cycle dependent, and we outline how the coordinate regulation of microRNA targets may influence cell cycle progression...
  21. ncbi request reprint Recent developments in DNA microarrays
    Daniel D Shoemaker
    Rosetta Inpharmatics, 12040 115th Avenue North East, Kirkland, Washington 98034, USA
    Curr Opin Microbiol 5:334-7. 2002
    ..Supporting this view, the number of applications of DNA microarray technology has since expanded exponentially. Here, we review recent advances in microarray technology and selected new applications of the technology...
  22. ncbi request reprint Expression profiling reveals off-target gene regulation by RNAi
    Aimee L Jackson
    Rosetta Inpharmatics LLC, 12040 115th Avenue NE, Kirkland, Washington 98034, USA
    Nat Biotechnol 21:635-7. 2003
    ..These results demonstrate that siRNAs may cross-react with targets of limited sequence similarity...
  23. pmc RNA interference-mediated silencing of mitotic kinesin KIF14 disrupts cell cycle progression and induces cytokinesis failure
    Michael Carleton
    Rosetta Inpharmatics LLC, 401 Terry Ave, N Seattle, Washington 98109, USA
    Mol Cell Biol 26:3853-63. 2006
    ..Furthermore, the link we observed between siRNA efficacy and phenotypic outcome indicates that distinct stages during cell cycle progression are disrupted by the differential modulation of KIF14 expression...
  24. pmc Gene expression changes associated with progression and response in chronic myeloid leukemia
    Jerald P Radich
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 103:2794-9. 2006
    ..These studies point to specific gene pathways that might be exploited for both prognostic indicators as well as new targets for therapy...
  25. ncbi request reprint Signatures of environmental exposures using peripheral leukocyte gene expression: tobacco smoke
    Johanna W Lampe
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Cancer Epidemiol Biomarkers Prev 13:445-53. 2004
    ..These findings suggest that expression patterns can be used to identify a complex environmental exposure in humans...
  26. ncbi request reprint Genetics of gene expression surveyed in maize, mouse and man
    Eric E Schadt
    Rosetta Inpharmatics, LLC, 12040 115th Avenue N E, Kirkland, Washington 98034, USA
    Nature 422:297-302. 2003
    ..We identify a gene expression pattern strongly associated with obesity in a murine cross, and observe two distinct obesity subtypes. Furthermore, we find that these obesity subtypes are under the control of different loci...
  27. ncbi request reprint Noise amidst the silence: off-target effects of siRNAs?
    Aimee L Jackson
    Rosetta Inpharmatics LLC, 401 Terry Avenue N, Seattle, WA 98109, USA
    Trends Genet 20:521-4. 2004
    ..In the meantime, caution is warranted in interpreting gene function and phenotypes resulting from RNAi experiments...
  28. pmc MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators
    Galina Gabriely
    Center of Neurologic Diseases, Brigham and Women s Hospital, 4 Blackfan Circle, HIM 758, Boston, MA 02115, USA
    Mol Cell Biol 28:5369-80. 2008
    ....
  29. doi request reprint Median absolute deviation to improve hit selection for genome-scale RNAi screens
    Namjin Chung
    Department of Automated Biotechnology, Merck Research Laboratories, North Wales, PA 19454, USA
    J Biomol Screen 13:149-58. 2008
    ....
  30. doi request reprint An efficient and fully automated high-throughput transfection method for genome-scale siRNA screens
    Namjin Chung
    Department of Automated Biotechnology, Merck Research Laboratories, North Wales, PA 19454, USA
    J Biomol Screen 13:142-8. 2008
    ..Transfection efficiency, performances of control siRNAs, and other quality metrics were monitored and demonstrated that the new, optimized transfection protocol produced high-quality results throughout the screen...
  31. ncbi request reprint A microRNA component of the p53 tumour suppressor network
    Lin He
    Watson School of Biological Sciences, Howard Hughes Medical Institute, Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, New York 11724, USA
    Nature 447:1130-4. 2007
    ..The p53 network suppresses tumour formation through the coordinated activation of multiple transcriptional targets, and miR-34 may act in concert with other effectors to inhibit inappropriate cell proliferation...
  32. ncbi request reprint Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies
    Ralf Kittler
    Max Planck Institute for Molecular Cell Biology and Genetics, Pfotenhauerstrasse 108, D 01307 Dresden, Germany
    Nat Methods 4:337-44. 2007
    ..Hence, the presented esiRNA libraries offer an efficient, cost-effective and specific alternative to presently available mammalian RNAi resources...
  33. ncbi request reprint Gene expression profiling predicts clinical outcome of breast cancer
    Laura J van 't Veer
    Division of Diagnostic Oncology, The Netherlands Cancer Institute, 121 Plesmanlaan, 1066 CX Amsterdam, The Netherlands
    Nature 415:530-6. 2002
    ..This gene expression profile will outperform all currently used clinical parameters in predicting disease outcome. Our findings provide a strategy to select patients who would benefit from adjuvant therapy...
  34. pmc Designing siRNA that distinguish between genes that differ by a single nucleotide
    Dianne S Schwarz
    Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
    PLoS Genet 2:e140. 2006
    ..Our data suggest that siRNAs can be designed to discriminate between the wild-type and mutant alleles of many genes that differ by just a single nucleotide...
  35. pmc Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors
    James L Riley
    Abramson Family Cancer Research Institute and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104 6160, USA
    Proc Natl Acad Sci U S A 99:11790-5. 2002
    ..Cytotoxic T lymphocyte antigen 4 (CTLA-4) engagement selectively blocked augmentation of gene regulations by CD28-mediated costimulation, but did not ablate gene regulation induced by TCR triggering alone...
  36. ncbi request reprint Synthetic shRNAs as potent RNAi triggers
    Despina Siolas
    Nat Biotechnol 23:227-31. 2005
    ..Maximal inhibition of target genes was achieved at lower concentrations and silencing at 24 h was often greater. These studies provide the basis for an improved approach to triggering experimental silencing via the RNAi pathway...
  37. ncbi request reprint A large-scale RNAi screen in human cells identifies new components of the p53 pathway
    Katrien Berns
    Division of Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Nature 428:431-7. 2004
    ..Furthermore, we describe siRNA bar-code screens to rapidly identify individual siRNA vectors associated with a specific phenotype. These new tools will greatly facilitate large-scale loss-of-function genetic screens in mammalian cells...
  38. pmc CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
    Richard V Parry
    Abramson Family Cancer Research Institute, 556 BRB II III, 421 Curie Blvd, University of Pennsylvania, Philadelphia, PA 19104, USA
    Mol Cell Biol 25:9543-53. 2005
    ..Together, these data suggest that CTLA-4 and PD-1 inhibit T-cell activation through distinct and potentially synergistic mechanisms...
  39. ncbi request reprint Minimizing the risk of reporting false positives in large-scale RNAi screens
    Christophe J Echeverri
    Cenix BioScience GmbH, Tatzberg 47, Dresden, 10307, Germany
    Nat Methods 3:777-9. 2006
    ....